遅く診断された乳児ポンペ病における短期集中アバルグルコシダゼアルファレジメント:症例報告
関連する実験動画
Updated: May 13, 2026

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.4K
Vincenza Gragnaniello1, Alice Pozza2, Chiara Cazzorla1
1Division of Inherited Metabolic Diseases, Department of Woman's and Child's Health, University Hospital of Padua, Via Giustiniani 2, 35128 Padua, Italy.
Reports (MDPI)
|February 20, 2026
まとめ
アヴァルグルコシダゼアルファ (40 mg/kg) の高用量週1回の投与が2ヶ月間行われ,重度のポムペ病の乳児発症患者の有意な改善を示した. この短期間の集中治療は安全で効果があり,正常な発達につながりました.
科学分野:
- バイオケミストリー バイオケミストリー
- 遺伝学 遺伝学とは
- 小児科は小児科です.
背景:
- 幼児発症ポンペ病 (IOPD) は,多動性心筋病症と低血圧症によって特徴づけられる重篤な疾患です.
- アバルグルコシダゼアルファは,ポンペ病に対する新しい酵素置換療法です.
- これまで治療を受けていないIOPD患者の最適な投与量は未定です.
研究 の 目的:
- 重度のIOPD患者におけるアバルグルコシダゼアルファの高用量,高頻度の治療法の安全性と有効性を評価する.
- 短期間の集中治療が臨床,生化学,運動の結果に与える影響を決定する.
主な方法:
- 重度のIOPDの3ヶ月の乳児は,アバルグルコシダゼアルファを隔週40mg/kgで投与され,その後2ヶ月間毎週40mg/kgにエスカレートされました.
- 臨床評価には,心臓機能 (LVMI,EF),運動発達,生化学マーカーなどが含まれていました.
- 治療の調整は,患者の反応と心臓機能のモニタリングに基づいて行われました.
主要な成果:
- 40 mg/kgを隔週に1度投与した初期治療では,心臓の悪化が示されました.
- 2ヶ月の集中治療 (週に40mg/kg) は,有害事象なしに,臨床的,生化学的,運動的な改善をもたらしました.
- 18ヶ月で,患者は正常な運動発達,心臓機能,バイオマーカーを示し,隔週ごとに40mg/kgの投与量に戻った.
結論:
- アヴァルグルコシダゼアルファの短期,高用量,高頻度の投与は,重症で遅れて診断されたIOPDに対する安全で効果的な戦略である可能性があります.
- このケースは,IOPD患者のアウトカムを改善するために,集中的な初期治療の潜在的な利点を示唆しています.
- これらの発見をより大きなコホートで確認するためにさらなる研究が必要である.
関連する概念動画
Glucose Transporters
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Inborn Errors of Metabolism
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Acute Pancreatitis I: Introduction
Acute pancreatitis is the sudden inflammation of the pancreas caused by the early activation of digestive enzymes, leading to the autodigestion of pancreatic tissue. This results in local inflammation and, in severe cases, systemic complications.EtiologyUnderstanding the underlying causes is crucial, as identifying the etiology guides treatment and anticipates complications. Acute pancreatitis can be triggered by various factors, typically grouped into the following clinical categories.Biliary...

